Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $46.71, for a total value of $934,200.00. Following the sale, the director now owns 3,540,857 shares of the company’s stock, valued at $165,393,430.47. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Simulations Plus Stock Up 1.7 %
Shares of NASDAQ SLP traded up $0.77 during trading on Tuesday, reaching $46.95. The company had a trading volume of 207,144 shares, compared to its average volume of 102,393. The company’s fifty day moving average price is $47.80 and its 200-day moving average price is $44.14. Simulations Plus, Inc. has a 12 month low of $32.69 and a 12 month high of $52.69. The stock has a market cap of $938.53 million, a P/E ratio of 86.58 and a beta of 0.72.
Simulations Plus (NASDAQ:SLP – Get Free Report) last announced its earnings results on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $17.31 million. During the same quarter in the prior year, the company earned $0.20 EPS. The firm’s revenue for the quarter was up 16.2% compared to the same quarter last year. As a group, equities analysts predict that Simulations Plus, Inc. will post 0.55 earnings per share for the current year.
Simulations Plus Announces Dividend
Analyst Upgrades and Downgrades
SLP has been the subject of a number of research analyst reports. Oppenheimer boosted their price target on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 13th. William Blair started coverage on Simulations Plus in a research report on Friday. They issued an “outperform” rating on the stock. Finally, Craig Hallum upped their price target on Simulations Plus from $51.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, June 13th.
View Our Latest Stock Report on SLP
Institutional Investors Weigh In On Simulations Plus
Institutional investors and hedge funds have recently made changes to their positions in the business. EntryPoint Capital LLC purchased a new stake in shares of Simulations Plus in the first quarter worth approximately $57,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $70,000. Connecticut Wealth Management LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $204,000. Janney Montgomery Scott LLC purchased a new stake in shares of Simulations Plus during the first quarter valued at approximately $208,000. Finally, Canton Hathaway LLC increased its position in shares of Simulations Plus by 25.0% during the fourth quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company’s stock valued at $224,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Stories
- Five stocks we like better than Simulations Plus
- Stock Average Calculator
- RXO Shares Surge Following New Acquisition Deal
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Why Invest in 5G? How to Invest in 5G Stocks
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.